• Monogram Biosciences (South San Francisco, California) said that, effective July 15, the HERmark Breast Cancer Assay will be available to physicians throughout the U.S. for assessment of HER2 status in patients with breast cancer. HERmark provides a precise and quantitative measurement of HER2 total protein and HER2 homodimer levels and will be offered as a CLIA-validated assay through Monogram's CAP-certified clinical laboratory. Physicians currently use semi-quantitative measures to determine HER2 status as an indicator of HER2 protein over-expression or HER2 gene amplification to determine whether or not to prescribe Herceptin. Inaccurate measurements of HER2 status may lead to inappropriate therapy selection. HERmark is a diagnostic that accurately quantifies HER2 total protein levels and HER2 homodimerization in patients with breast cancer. HERmark is a CLIA-validated assay that is performed exclusively in Monogram's CAP-certified clinical reference laboratory in South San Francisco. Robust, accurate, sensitive and reproducible measurements of HER2 status are reported to physicians with a turnaround time of seven days. Monogram makes products to guide and improve treatment of serious infectious diseases and cancer.

• Radi Medical (Uppsala, Sweden) reported improvements to its latest-generation pressure-sensing guide wire, PressureWire Certus. The upgraded PressureWire Certus features a new ergonomically designed proximal connector which provides three key advantages for physicians. The new entry funnel allows for wire reconnection into the proximal connector, while also exhibiting less insertion friction. In addition, the new locking cap provides positive reinforcement when the wire and the connector are locked in place via a user intuitive on and off twist function. Radi Medical specializes in interventional cardiology products.

• Rosetta Genomics (Jersey City, New Jersey) said that the results of a study conducted by its scientists and collaborators and describing the use of microRNAs in accurately differentiating primary from metastatic tumors of the brain, have been published online in the peer-reviewed journal Brain Pathology. The findings demonstrate microRNAs' potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify primary tumors in patients with brain cancers. Rosetta Genomics specializes in microRNA-based diagnostic and therapeutic products.

• Trumpf Medical Systems (Charleston, South Carolina) has introduced what it said is the first in-light high-definition (HD) operating room camera. The TruVidia HD captures and transmits images with 1080 lines horizontal resolution and 2 million pixels. Images, captured in wide-screen format, can be transmitted for telemedicine applications and displayed on screen for education. Remote consultations can be conducted with a greater degree of confidence as the HD images essentially place the remote physicians in the OR. The TruVidia HD is integrated into the central handle of the Trumpf iLED surgical light. The camera also is available on a separate arm. Camera functions, including zoom and rotate can be controlled directly from the sterile field or from the control panel. Captured still images and even entire video sequences can be shared and archived on USB memory sticks. Trumpf Medical Systems makes patient care and efficiency solutions to medical facilities.

• Vermillion (Fremont, California) said it has submitted a 510(k) application to the FDA for its ovarian tumor triage test known as OVA1. Previously, the OVA1 prospective clinical trial met its primary endpoints, indicating that the test is capable of stratifying women with pelvic masses into high- and low-risk categories to help determine whether the patient should be referred to a specialist prior to surgery. Vermillion is a molecular diagnostics company.